Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
3.730
-0.060 (-1.58%)
Dec 5, 2025, 4:00 PM EST - Market closed
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
$999,349
Profits / Employee
-$348,128
Market Cap
878.15M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ESPR News
- 15 days ago - Esperion Therapeutics, Inc. (ESPR) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 17 days ago - Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease - GlobeNewsWire
- 23 days ago - Wasatch Ultra Growth Fund Q3 2025 Top Contributors And Detractors - Seeking Alpha
- 24 days ago - Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript - Seeking Alpha
- 25 days ago - Esperion Therapeutics: Still An Attractive Risk/Reward Narrative As The Earnings Clock Ticks Toward Profitability - Seeking Alpha
- 4 weeks ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer - GlobeNewsWire